IN ENILIS et al

A..../ney's Docket No.: 09011-002002

Applicant: JENS CHR. JESENIUS et al

Serial No.:

Filed : June 4, 2001

Page : 2

REMARKS

Attached is a marked-up version of the changes being made by the current amendment.

Applicant asks claims 1-11, 22 and 28 be allowed. Please apply any other charges or

credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 4 201

Lee Crews Reg. No. 43 567

John W. Freeman, Esq. Reg. No. 29,066

Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110-2804 Telephone: (617) 542-5070 Facsimile: (617) 542-8906

20270705.doc

Applicant: JENS CHR. JE. SENIUS et al.

imovis Docket No.

rney's Docket No.: 09011-002002

Serial No.:

Filed : June 4, 2001

Page: 3

Version with markings to show changes made

In the specification:

Paragraph beginning at page page number, line line number has been amended as follows:

This application is a divisional (and claims the benefit of priority under 35 USC 120) of U.S. Application Serial No. 09/054,218, filed April 2, 1998, which claims [benefit] priority from U.S. Provisional Application Serial No. 60/042,678, filed April 2, 1997. The disclosure of the prior application is considered part of (and is incorporated by reference in) the disclosure of this application [hereby incorporated by reference].

In the claims:

Claims 12-21, 23-27, and 29-39 have been cancelled.

Claim 22 has been amended as follows:

22. (Amended) A pharmaceutical composition comprising the polypeptide of claim 1 [or the antibody of claims 18 or 19].